Business
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017
USRM Posts 25% Nine Month Revenue Increase From 3Q 2017.
About this update from U.s. Stem Cell, Inc.
[{"type":"text","content":"\n\n\n\nUSRM Posts 25% Nine Month Revenue Increase From 3Q 2017\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nUSRM Posts 25% Nine Month Revenue Increase From 3Q 2017\nProfit Margins Continue to Increase As Costs And Operating Expenses Decrease\nPR Newswire\nSUNRISE, Fla., Nov. 7, 2018\n\n\n\nSUNRISE, Fla., Nov. 7, 2018 /PRNewswire/ -- U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced third quarter results for this year and comparatively from last year, for the nine months ended Sept. 30, 2018.\n\n \n \n\n \nAs has been the trend for the past several years, revenue continues to rise -- almost $1M or 25% for the period compared to the same period last year --  from $4.04M in 3Q 2017 to $5.03M in 3Q 2018.  Gross profit margins also increased, $723K or 26.8%, from $2.69M to $3.42M for the same time period.  Operating expenses decreased $850K or 42%, from $2.02M to $1.17M.  Net Loss from operations decreased $838K or 79.3%, from $1M to $218K during the same nine months ended this year versus last.\n\"Our financials directly reflect the success of our ongoing efforts to simultaneously expand and streamline operations to continue to serve the increasing market demand for stem cell therapy and regenerative health services,\" said Mike Tomas, President and CEO of U.S. Stem Cell, Inc.  \"Driving innovative therapies while helping to define and set industry standards requires a delicate balance.  We are working hard to achieve that balance, and I believe our third quarter financials demonstrate that effort.\"  \nFor two consecutive years, U.S. Stem Cell, Inc., has continued to sustain substantial revenue growth, which may be attributable to an increased awareness of stem cell therapy, as Americans seek alternatives to pain management and opioids.  The Company has also been instrumental in providing more than ten thousand stem cell procedures in the past 19 years for a variety of indications, including orthoped...